Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430742 | 1.00 | IDO1 (0.53) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL16995185 | 1.00 | IDO1 (0.53) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL477416 | 1.00 | IDO1 (0.53) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL8705439 | 0.98 | KDM4E (0.53) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL3310267 | 0.93 | CYP1A2 (0.53) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL477699 | 0.89 | CYP1A2 (0.56) | IDO1KDM4ECYP1A2CYP2D6CYP3A4 | |
| SCHEMBL19645377 | 0.89 | CYP1A2 (0.56) | IDO1KDM4ECYP1A2CYP2D6CYP3A4 | |
| SCHEMBL23652176 | 0.81 | HRH3 (0.45) | IDO1DHODHKDM4ECYP1A2CYP2D6 | |
| SCHEMBL8036930 | 0.81 | DHODH (0.56) | DHODHKDM4ETSHRKMT2AHRH3 | |
| SCHEMBL10021103 | 0.79 | DHODH (0.58) | IDO1DHODHCYP1A2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466949-A1 | TRICYCLIC COMPOUND AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3087071-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-9751879-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| CN-106397117-A | Reduction alcoholization and resolution method of cyclohexyl phenyl ketone | 安徽爱有澄生物科技有限公司 | 2017-02-15 | — | — | CN | disclosed |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3087071-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9458156-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| WO-2015100282-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8563786-B2 | Method for producing optically active alcohol | MITSUI CHEMICALS, INC. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-04-12 | — | — | US | disclosed |
| EP-2412694-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | Mitsui Chemicals, Inc. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | IDO1 1728/4885DHODH 378/4885KDM4E 1945/4885 |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | IDO1 2249/4885DHODH 523/4885KDM4E 2234/4885 |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | IDO1 2249/4885DHODH 523/4885KDM4E 2234/4885 |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | TP53, TK2, TOP2A | IDO1 1423/4885DHODH 398/4885KDM4E 2036/4885 |
| US-20120088938-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | ADH1A, ADH1C, FHIT | IDO1 4327/4885DHODH 871/4885KDM4E 2522/4885 |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | IDO1 2249/4885DHODH 523/4885KDM4E 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.